A study by Australia’s Monash University has highlighted the benefit for pregnant women with multiple sclerosis (MS) who continue to take a disease-modifying treatment during and after pregnancy.
Using data from the international MSBase registry, the findings published in Neurology, revealed that women with MS who continued to take natalizumab through and after their pregnancy, had a decrease in relapse rates by up to 89%.
Natalizumab was brought to market by Biogen (Nasdaq: BIIB) under the brand name Tysabri.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze